📄 medicine

Diagnostic Concordance of mpMRI and Ga68 PSMA PET/CT on Localization of Prostatic Lesions in Patients with Suspected Prostate Cancer and Negative TRUS-Guided Biopsy

This study demonstrates that in patients with rising PSA levels and prior negative biopsies, the combined interpretation of mpMRI and Ga68 PSMA PET/CT achieves high diagnostic concordance with histopathology, significantly improving the localization and detection of clinically significant prostate cancer.

Original authors: Abhishek Choube, Shushant Shandilya, Amrut Phonde, Prashant Kumar Rai, Sushant Trakroo, Nishan Gaudani

Published 2026-06-24

📖 4 min read☕ Coffee break read

CC BY 4.0

Original authors: Abhishek Choube, Shushant Shandilya, Amrut Phonde, Prashant Kumar Rai, Sushant Trakroo, Nishan Gaudani

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ✨ This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer

The Big Problem: The "Blind" Search

Imagine you are looking for a specific, dangerous weed growing in a large, complex garden (the prostate). The gardeners (doctors) have a standard way of checking: they use a long stick with sensors (a TRUS-guided biopsy) to poke holes in the soil and pull up small samples.

In this study, the gardeners had already poked the soil 12 times in a row and found nothing but grass. However, the "alarm system" (the patient's PSA blood test) kept screaming that a weed was definitely there. The gardeners were stuck: the standard poking method said "nothing," but the alarm said "danger."

The New Tools: Two Different Flashlights

To solve this mystery, the researchers gave the gardeners two high-tech flashlights to scan the garden before trying to dig again:

mpMRI (The Detailed Map): This is like a super-high-resolution 3D map of the garden. It shows the shape of the soil, the water flow, and where things look weird. It's great at seeing the general layout, but sometimes it gets confused by old scars or inflammation (like confusing a pile of leaves for a weed).
Ga68 PSMA PET/CT (The Glow-in-the-Dark Tracker): This is a special flashlight that only shines on the specific chemical signature of the weed itself. If the weed is there, it glows. This is great at finding weeds that are hiding in the shadows or deep in the soil where the map might miss them.

The Experiment

The researchers took 43 patients who were in this exact "stuck" situation (high alarm, but the first 12 pokes found nothing). They used both flashlights on these patients and then performed a new, smarter dig (a targeted biopsy) exactly where the lights pointed.

What They Found

1. The "Glow" Light Found the Weed
When they dug where the lights pointed, they found cancer (the weed) in 90.7% of the patients. This proves that even though the first 12 pokes missed it, the cancer was definitely there. The standard method had simply missed the target.

2. Where the Lights Shone
The study found that the "Glow Light" (PSMA PET/CT) was particularly good at finding weeds in the front and tips of the garden.

Analogy: Think of the garden as a house. The old poking method was like checking the front door and the living room. The new "Glow Light" was able to see into the attic and the basement—places the old method couldn't reach easily. These are "blind spots" where the first biopsy failed.

3. Do the Two Lights Agree?
The researchers checked if the "Map" (MRI) and the "Glow Light" (PET/CT) pointed to the same spots.

The Verdict: They agreed quite well, especially on the most dangerous parts of the garden (like the base of the prostate or the seminal vesicles).
The Kicker: When the gardeners used both lights together, they were the most accurate. Using just one light was good, but using both gave them the best confidence in exactly where to dig.

4. The "Density" Test
They also tried to use a calculation called "PSA Density" (how much alarm is there per size of the garden) to guess if the weed was dangerous.

The Result: It was a bit of a weak guess. It wasn't very good at telling the difference between a harmless patch of grass and a dangerous weed. The lights were much better at this job.

The Main Takeaway

For patients who are worried about prostate cancer but had a "clean" first test, this study suggests:

Don't just keep poking blindly; the cancer might be hiding in the "blind spots" (front or tips).
Using both the detailed Map (MRI) and the Glow Light (PSMA PET/CT) together is the best way to find the exact location of the cancer.
When they used both tools, they successfully found the dangerous cancer in over 9 out of 10 patients who were previously told they were fine.

In short: When the standard search fails, combining a detailed map with a chemical tracker helps doctors find the hidden trouble spots they missed the first time.

Technical Summary: Diagnostic Concordance of mpMRI and Ga68 PSMA PET/CT in Patients with Negative TRUS-Guided Biopsy

Problem Statement
Patients presenting with persistently rising prostate-specific antigen (PSA) levels despite a negative transrectal ultrasound (TRUS)-guided systematic biopsy represent a significant diagnostic challenge in urologic practice. Traditional 12-core systematic biopsies frequently yield false-negative results, particularly when tumors are located in anterior, apical, or small-volume regions that are difficult to sample via standard approaches. Repeated systematic biopsies increase patient morbidity without guaranteeing the detection of clinically significant prostate cancer (csPCa). While multiparametric magnetic resonance imaging (mpMRI) has improved lesion detection, it faces limitations in patients with post-biopsy hemorrhage, prostatitis, or equivocal PI-RADS 3 lesions. Consequently, there is a need to evaluate advanced molecular imaging, specifically Gallium-68 prostate-specific membrane antigen (Ga68 PSMA) PET/CT, and its anatomical concordance with mpMRI to improve the localization of suspicious lesions in this specific high-risk cohort.

Methodology
This observational study was conducted at a tertiary care referral center between 2020 and 2021. The study population consisted of 43 consecutive patients who met the following criteria:

Persistent clinical suspicion of prostate cancer (defined as continuously rising serum PSA) despite a prior negative 12-core systematic TRUS-guided biopsy.
A pre-biopsy mpMRI demonstrating a PI-RADS score ≥3 lesion.
Completion of both repeat mpMRI and Ga68 PSMA PET/CT within 6 months of the negative biopsy.
Subsequent targeted biopsy of lesions identified on imaging.

Imaging and Analysis Protocols:

mpMRI: Performed using standardized protocols (T2-weighted, DWI, ADC mapping, DCE) and categorized according to PI-RADS version 2.
Ga68 PSMA PET/CT: Conducted following intravenous administration of a Ga68-labeled PSMA tracer. Focal uptake exceeding background activity was considered positive. SUVmax values were recorded.
Histopathology: Targeted biopsies served as the reference standard. Findings were graded using the Gleason system and International Society of Urological Pathology (ISUP) classification. Clinically significant prostate cancer (csPCa) was defined using Epstein criteria.
Statistical Analysis: Diagnostic performance metrics (sensitivity, specificity, PPV, NPV, accuracy) were calculated. Concordance between mpMRI, Ga68 PSMA PET/CT, and histopathology was assessed on a lesion-based basis using Cohen's kappa ( $\kappa$ ) statistics, interpreted via Landis and Koch criteria.

Key Results

Diagnostic Yield: Histopathology confirmed adenocarcinoma in 39 of 43 patients (90.7%). Among these, 33 patients (84.6%) met the criteria for clinically significant prostate cancer.
Lesion Localization:
- mpMRI: Predominantly identified lesions in the peripheral zone and posterior aspect of the prostate.
- Ga68 PSMA PET/CT: Demonstrated high detection rates in areas often missed by TRUS, identifying anterior lesions in 60.5% of patients and apical involvement in 48.8%. Peripheral zone lesions were the most common finding (67.4%).
Concordance Analysis:
- Combined Modality: The combined interpretation of mpMRI and Ga68 PSMA PET/CT achieved the highest concordance with histopathology at 90.8%.
- Individual Modalities: mpMRI alone showed 80% concordance, while Ga68 PSMA PET/CT alone showed 72.3% concordance.
- Anatomical Agreement: The highest agreement between the two imaging modalities was observed for seminal vesicle invasion ( $\kappa=0.744$ ), left-lobe involvement ( $\kappa=0.671$ ), and basal lesions ( $\kappa=0.624$ ). Agreement was moderate for anterior and posterior lesions ( $\kappa=0.595$ ) and fair for lymph node involvement ( $\kappa=0.392$ ).
PSA Density: A PSA density cutoff of 0.22 showed modest discriminatory ability for csPCa (AUC 0.614), with a sensitivity of 63.64% and specificity of 50.00%.

Key Contributions and Claims
The study contributes to the literature by evaluating the anatomical concordance of mpMRI and Ga68 PSMA PET/CT specifically in the challenging subgroup of patients with rising PSA and prior negative biopsies. The authors claim that:

High Diagnostic Yield: Ga68 PSMA PET/CT is highly effective in this population, detecting adenocarcinoma in 90.7% of patients undergoing targeted biopsy.
Complementary Value: While mpMRI and Ga68 PSMA PET/CT show good concordance, Ga68 PSMA PET/CT is particularly useful for identifying anterior and apical lesions, which are common blind spots for conventional TRUS-guided biopsy.
Superiority of Combined Interpretation: The integration of both imaging modalities yields the highest concordance with histopathological findings, suggesting that combined interpretation improves the targeting of clinically significant prostate cancer during repeat biopsy procedures.
Limitations of PSA Density: The study notes that while PSA density is an adjunctive marker, imaging-based localization appears superior for identifying clinically significant lesions in this specific cohort.

Significance
The authors posit that their findings underscore the limitations of conventional TRUS-guided systematic biopsy in patients with persistent clinical suspicion. The high malignancy detection rate (90.7%) in this cohort highlights the value of advanced imaging-guided lesion targeting. The study concludes that combined interpretation of mpMRI and Ga68 PSMA PET/CT may improve the localization of suspicious prostatic lesions and facilitate the detection of clinically significant disease, potentially reducing the need for repeated invasive procedures. The authors acknowledge limitations, including the single-center nature, small sample size, and reliance on targeted biopsy rather than whole-mount prostatectomy for histological confirmation, and call for future multicentric prospective studies to define the optimal integration of PSMA PET/CT into diagnostic pathways.